After half a stunning year, a strong month ᅠ.
Aborihan Pharmaceuticals has posted a good monthly report after an incredible six months. Mahar's income is a new record for the company with about 1.05% and has a growth of 218% from point to point. The monthly income since March was higher than the previous month. Its average rose from 374 billion tomans in the first season to 809 billion tomans in the second season. The income for seven months increased by 123% to about 4.6 Hamats, which is 36% more than last year. The engine of this growth is rates and the average sales rate almost triples.
ᅠ value investment ᅠ.